NCT02328014 2025-12-09
Acalabrutinib (ACP-196) in Combination With ACP-319, for Treatment of B-Cell Malignancies
Acerta Pharma BV
Phase 1/2 Completed
Clinical Trials
6 trialsNCT02180711 2025-10-15
Study of Acalabrutinib Alone or in Combination Therapy in Subjects With B-cell Non-Hodgkin Lymphoma
Acerta Pharma BV
Phase 1/2 Active not recruiting
NCT04257578 2025-10-08
Acalabrutinib and Anti-CD19 CAR T-cell Therapy for the Treatment of B-cell Lymphoma
University of Washington
Phase 1/2 Active not recruiting
NCT04419389 2025-03-17
R/R
Aprea Therapeutics
Phase 1/2 Terminated
NCT03571308 2023-09-28
ACCEPT
University Hospital Southampton NHS Foundation Trust
Phase 1/2 Completed
NCT04502394 2022-08-04
Safety and Efficacy of KRT-232 in Combination With Acalabrutinib in Subjects With R/R DLBCL or R/R CLL
Kartos Therapeutics, Inc.
Phase 1/2 Unknown